ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1557

De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

Sinem Nihal Esatoglu1, Ozge Sonmez2, Didar Ucar3, Elif Kaymaz4, Yesim Ozguler5, Serdal Ugurlu6, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko7, Vedat Hamuryudan1, Ugur Uygunoglu8, Zekayi Kutlubay9 and Gulen Hatemi1, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Istanbul, Turkey, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 8Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Dermatology, Istanbul, Turkey

Meeting: ACR Convergence 2023

Keywords: Anti-TNF Drugs, Behçet's Syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet’s syndrome (BS). Treatment response may show variability across organ manifestations of BS. We aimed to determine the frequency of de novo manifestations during adalimumab (ADA) treatment.

Methods: We conducted a chart review of 285 BS patients who received ADA in our Behçet Disease Research Center. Demographic data, reasons for initiating ADA, concurrent medications, previous treatments, and treatment outcomes were recorded. We defined de novo manifestations as new BS manifestations that had not manifested prior to the initiation of ADA treatment. For patients with vascular involvement, a new vascular event at another vessel was also considered as a de novo manifestation.

Results: The main reasons for ADA use among our 285 patients were uveitis in 100 patients (35%), vascular involvement in 70 (%25), arthritis in 56 (%20), mucocutaneous involvement in 39 (%14), parenchymal central nervous system involvement in 8 (%3), and gastrointestinal involvement in 9 (%3). Among these patients, 12 (4%) developed a de novo manifestation. De novo manifestations that occurred in 12 patients were vascular involvement in 5 patients, arthritis in 3, anterior uveitis in 2, and parenchymal central nervous system involvement in 2. The primary reasons for ADA treatment were vascular involvement in 3, arthritis in 3, uveitis in 3, and mucocutaneous involvement in 2 of these 12 patients. Among these 12 patients, 8 (61%) were using concomitant conventional immunosuppressive treatment at the time of occurrence of de novo manifestations.

Treatment with ADA was intensified in 3 patients by shortening the intervals to 1 week, along with the addition of high dose glucocorticoids in one patient. In the 3 patients, ADA was switched to another agent (infliximab in 2 patients, certolizumab in 1 patient). Only glucocorticoids were added in two patients, azathioprine along with high dose corticosteroids in one patient and colchicine in one patient. Two patients who had developed anterior uveitis were initiated topical treatment (Table).

Conclusion: De novo manifestations occurred in 4% of BS patients treated with adalimumab. Majority of these (75%) were major organ involvement, mainly vascular involement. None of the patients developed posterior uveitis, the 2 patients with uveitis developing during ADA had anterior uveitis that was controlled with topical agents.

Supporting image 1

Demographics, characteristics, de novo manifestations and treatment of de novo manifestations of
12 patients

Supporting image 2


Disclosures: S. Esatoglu: None; O. Sonmez: None; D. Ucar: None; E. Kaymaz: None; Y. Ozguler: None; S. Ugurlu: None; E. Seyahi: None; M. Melikoglu: None; I. Fresko: None; V. Hamuryudan: None; U. Uygunoglu: None; Z. Kutlubay: None; G. Hatemi: None.

To cite this abstract in AMA style:

Esatoglu S, Sonmez O, Ucar D, Kaymaz E, Ozguler Y, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Hamuryudan V, Uygunoglu U, Kutlubay Z, Hatemi G. De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/de-novo-manifestations-during-adalimumab-treatment-in-behcet-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/de-novo-manifestations-during-adalimumab-treatment-in-behcet-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology